Pfizer has agreed to pay $93 million to resolve antitrust claims filed by drug distributors, who accuse Pfizer of colluding with Indian generic company Ranbaxy Laboratories to delay the sale of a lower priced cholesterol drug called Lipitor. Multiple Lipitor buyers disclosed this agreement in a document filed in a US court on February 14th.